Crinetics Pharmaceuticals
2008
FOUNDED
PUBLIC
STATUS
41-50
EMPLOYEES
CRNX
STOCK SYMBOL
$18.37
SHARE PRICE
(As of Thursday Closing)
Description
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 10222 Barnes Canyon Road
- Building No. 2
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Crinetics Pharmaceuticals’s full profile, request a free trial.
Crinetics Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $14.33 - $36.95 | $445M | $19.18 | -$1.84 | 56.5K | 24.2M |
Crinetics Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 224,898 | 551,215 | ||
| Revenue | 1,653 | 2,428 | 2,045 | 589 |
| EBITDA | (47,306) | (28,392) | (9,047) | (5,953) |
| Net Income | (44,368) | (27,115) | (9,157) | (6,019) |
| Total Assets | 142,509 | 171,415 | 15,598 | 12,599 |
| Total Debt | 5,740 | 212 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Crinetics Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Crinetics Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookCrinetics Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Crinetics Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookCrinetics Pharmaceuticals Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | 00 | 00000 | 000000000 | 00000 |
| 0000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 00000000 | 00000 |
| 00000000000 | Angel-Backed | Culver City, CA | 00000 | 000000000000 | 00000 | |
| 00000 | Venture Capital-Backed | Pittsburgh, PA | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000000 0000000000 | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 00000000 |
Crinetics Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Crinetics Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookCrinetics Pharmaceuticals Executive Team (7)
1 Former Executive
You’re viewing 5 of 7 executives. Get the full list »Crinetics Pharmaceuticals Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| David Allison Ph.D | 5AM Ventures | Board Observer | 000 0000 | |
| Jack Bech Nielsen | Vivo Capital | Board Member | 000 0000 | |
| Matthew Fust | Self | Board Member | 000 0000 | |
| Richard Struthers Ph.D | Crinetics Pharmaceuticals | Co-Founder, Chief Executive Officer & Board Member | 000 0000 | |
| Stephen Kaldor Ph.D | Versant Venture Management | Board Member | 000 0000 |
3 Former Board Members
You’re viewing 5 of 10 board members. Get the full list »